Workflow
Nyxoah(NYXH)
icon
Search documents
Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares
GlobeNewswire News Room· 2024-05-31 06:00
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares Mont-Saint-Guibert, Belgium – May 31, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the closing of its previously announced underwritten public offering in t ...
Information on the Total Number of Voting Rights and Shares
Newsfilter· 2024-05-28 20:30
Information on the Total Number of Voting Rights and Shares Mont-Saint-Guibert (Belgium), May 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. * * REGULATED INFORMATION Attachment * Share capital: EUR 5,851,253.43 Total number of securities carrying voting rights: 34,060,390 (all ordinary shares) Total number o ...
Nyxoah Announces Pricing of Offering
Newsfilter· 2024-05-23 13:59
Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in th ...
Nyxoah Announces Pricing of Offering
globenewswire.com· 2024-05-23 13:59
About Nyxoah REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Pricing of Offering Mont-Saint-Guibert, Belgium – May 23, 2024, 3:50 pm CET / 9:50 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today the pricing of an underwritten public offering in the United States, which includes shares sold in a private offering to ...
Nyxoah Announces Reduction of the Maximum Amount Available Under its At the-Market Equity Offering Program
Newsfilter· 2024-05-22 20:10
Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium – May 22, 2024, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today that it has reduced the maximum amount of 6,000,000 ordinary shares available for issuance under its "at- ...
Nyxoah Announces Reduction of the Maximum Amount Available Under its At the-Market Equity Offering Program
globenewswire.com· 2024-05-22 20:10
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium – May 22, 2024, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today that it has reduced the maximum amount of 6,000,000 ordinary sha ...
Nyxoah Announces Proposed Offering of Ordinary Shares
globenewswire.com· 2024-05-22 20:05
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Announces Proposed Offering of Ordinary Shares Mont-Saint-Guibert, Belgium – May 22, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), announced today the commencement of a proposed underwritten public offering in the United States, which may include shares sold in a ...
Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024
Newsfilter· 2024-05-13 20:30
Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024 Mont-Saint-Guibert, Belgium – May 13, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the first quarter 2024 on Tuesday, May 14, 2024, after market close. Company management will host a conferen ...
Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 12, 2024
Newsfilter· 2024-05-10 05:00
REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the annual and the extraordinary shareholders' meetings of the Company to be held on June 12, 2024 The board of directors of the Company is pleased to invite its securities holders to attend the annual shareholders' meeting of the Company, to be held on Wednesday, June 12, 2024 at 2:00 p.m. CET at the Company's sea ...
Nyxoah(NYXH) - 2023 Q4 - Annual Report
2024-03-20 20:06
Table of Contents As filed with the Securities and Exchange Commission on March 20, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti ...